Beyond first-line systemic treatment for metastatic urothelial carcinoma of the bladder

• E. El Rassy ^[2] ; T. Assi ^[2] ; Z. Bakouny ^[2] ; N. Pavlidis ^[1] ; J. Kattan ^[2]
  1. [1] University of Ioannina

     University of Ioannina

     Dimos Ioánnina, Grecia

     
  2. [2] Hotel Dieu de France University Hospital. Beirut, Lebanon
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 21, Nº. 3, 2019, págs. 280-288
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Metastatic urothelial carcinoma of the bladder is a rarely curable disease. Patients receive systemic therapy with limited response rates and survival benefits. The rescue regimens of these patients who have failed first-line treatment had remained problematic until the recent advances. Several trials with novel regimens, including immune checkpoint inhibitors and targeted therapy, to salvage relapsed urothelial carcinoma of the bladder have recently been published. However, the choice of an optimal treatment regimen remains challenging in the absence of randomized trials comparing regimen sequences. Daily clinical cases provoke the question of whether there is a preferred second-line regimen. This paper provides an overview of recent trials and proposes a management algorithm based on subgroup analyses and prognostic features.